Management of Metastatic Colorectal Carcinoma with GcMAF Forte and Thymus Peptides: A Case ReportDmitry Klokol* and Mikhail Teppone
Stellar Biomolecular Research, Germany
- *Corresponding Author:
- Dmitry Klokol
Stellar Biomolecular Research
E-mail: [email protected]
Received date: July 11, 2016; Accepted date: August 18, 2016; Published date: August 31, 2016
Citation: Klokol D, Teppone M (2016) Management of Metastatic Colorectal Carcinoma with GcMAF Forte and Thymus Peptides: A Case Report. J Clin Cell Immunol 7:449. doi: 10.4172/2155-9899.1000449
Copyright: © 2016 Klokol D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In the recent years immunotherapy has gained important role in cancer management. Immunostimulating effects of thymus-derived peptides on carcinogenesis have been actively studied in both animals and humans. Gc protein derived macrophage-activating factor (GcMAF) was found to have potent effect on macrophage phagocytic activity. Immunostimulating effects of GcMAF and peptides of thymus can be effectively combined together and with other treatment modalities of cancer. The current case report demonstrates outcomes of combination of GcMAF Forte and HT Thymus (peptides of thymus) in the management of metastatic colorectal adenocarcinoma. This case study suggests that individually prescribed immunotherapy can be a promising alternative in management of advance forms of cancer, especially when options of treatment are limited.